BioTime, Inc. announced that it has entered into a research and option agreement with Orbit Biomedical Limited. Under the terms of the agreement, BioTime and Orbit Biomedical will collaborate on the use of Orbit Biomedical’s proprietary injection technology to deliver OpRegen for the treatment of dry age-related macular degeneration. Under the terms of the exclusive 12 month agreement, BioTime and Orbit Biomedical plan to investigate the safety and utility of Orbit Biomedical’s surgical delivery technology in the ongoing Phase I/II clinical study of OpRegen for the treatment of dry-AMD.